Coalition signers, including AMAC, are concerned that the regulation could distort market dynamics and push the costs of providing health goods and services onto nearly every payer, including patients, providers, insurers, and manufacturers. Furthermore, the regulation could lead to less capital for manufacturers developing new treatments and less private sector negotiation over drug prices. July … Continue reading AMAC Joins Coalition to Oppose CMS Regulation That Could Raise Drug Prices for Payers